Citations 2
A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam
Sharara, Sima L. , Diaz, Lorena, Asempa, Tomefa E, Martinez, Jose R W, Canales, Nicolas, Bergman, Yehudit , Murphy, Shannon G. , Karaba, Sara M. , Clark, Andrew E. , Zurawski, Daniel V, Cosgrove, Sara E, Simner, Patricia J, Munita, José M. , Tamma, Pranita D. , Tamma, Pranita D , Clark, Andrew E. , Karaba, Sara M , Bergman, Yehudit , Munita, Jose M , Sharara, Sima L. , Díaz, Lorena , Asempa, Tomefa E. , Canales, Nicolás, Murphy, Shannon G. , Zurawski, Daniel V. , Cosgrove, Sara E. , Simner, Patricia J.
Clinical Infectious Diseases | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract We report an eightfold increase in sulbactam-durlobactam MICs in a carbapenem-resistant Acinetobacter baumannii cerebrospinal fluid isolate recovered after 14 days of sulbactam-durlobactam plus meropenem therapy. Treatment-emergent mutations in the AdeFGH efflux system were identified, accompanied by a 166-fold increase in adeG expression. Efflux pump inhibition restored sulbactam-durlobactam susceptibility.
Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists
Wenzler, Eric , Maximos, Mira , Asempa, Tomefa E. , Biehle, Lauren , Hirsch, Elizabeth B. , Hirsch, Elizabeth B , Schuetz, Audrey N.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | February 24, 2023 | Volume: 43 | Issue: 4 | Pages: 264-278
Abstract Antimicrobial susceptibility testing (AST) is a critical function of the clinical microbiology laboratory and is essential for optimizing care of patients with infectious diseases, monitoring antimicrobial resistance (AMR) trends, and informing public health initiatives. Several methods are available for performing AST including broth microdilution, agar dilution, and disk diffusion. Technological advances such as the development of commercial automated susceptibility testing platforms and the advent of rapid diagnostic tests have improved the rapidity, robustness, and clinical application of AST. Numerous accrediting and regulatory agencies are involved in the process of AST and setting and revising breakpoints, including the U.S. Food and Drug Administration and the Clinical and Laboratory Standards Institute. Challenges to optimizing AST include the emergence of new resistance mechanisms, the development of new antimicrobial agents, and generation of new data requiring updates and revisions to established methods and breakpoints. Together, the challenges in AST methods and their interpretation create important opportunities for well‐informed clinicians to improve patient outcomes and provide value to antimicrobial stewardship programs, especially in the setting of rapidly changing and increasing AMR. Addressing AST challenges will involve continued development of new technologies along with collaboration between clinicians and the laboratory to facilitate optimal antimicrobial use, combat the increasing burden of AMR, and inform the development of novel antimicrobials. This updated primer serves to reinforce important principles of AST, and to provide guidance on their implementation and optimization.